CN112955222A - 用于治疗患有类风湿性关节炎的个体的方法和组合物 - Google Patents

用于治疗患有类风湿性关节炎的个体的方法和组合物 Download PDF

Info

Publication number
CN112955222A
CN112955222A CN201980065880.1A CN201980065880A CN112955222A CN 112955222 A CN112955222 A CN 112955222A CN 201980065880 A CN201980065880 A CN 201980065880A CN 112955222 A CN112955222 A CN 112955222A
Authority
CN
China
Prior art keywords
individual
antibody
antigen
rheumatoid arthritis
interleukin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980065880.1A
Other languages
English (en)
Chinese (zh)
Inventor
A·博亚帕蒂
N·格拉哈姆
T·木村
J·米斯希德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Original Assignee
Sanofi Biotechnology SAS
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Biotechnology SAS, Regeneron Pharmaceuticals Inc filed Critical Sanofi Biotechnology SAS
Publication of CN112955222A publication Critical patent/CN112955222A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Rehabilitation Therapy (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
CN201980065880.1A 2018-08-29 2019-08-28 用于治疗患有类风湿性关节炎的个体的方法和组合物 Pending CN112955222A (zh)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201862724212P 2018-08-29 2018-08-29
US62/724,212 2018-08-29
US201862747301P 2018-10-18 2018-10-18
US62/747,301 2018-10-18
US201962798697P 2019-01-30 2019-01-30
US62/798,697 2019-01-30
US201962824399P 2019-03-27 2019-03-27
US62/824,399 2019-03-27
US201962856431P 2019-06-03 2019-06-03
US62/856,431 2019-06-03
US201962858443P 2019-06-07 2019-06-07
US62/858,443 2019-06-07
EP19192387.9 2019-08-19
EP19192387 2019-08-19
PCT/US2019/048460 WO2020047029A1 (en) 2018-08-29 2019-08-28 Methods and compositions for treating subjects having rheumatoid arthritis

Publications (1)

Publication Number Publication Date
CN112955222A true CN112955222A (zh) 2021-06-11

Family

ID=67851236

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980065880.1A Pending CN112955222A (zh) 2018-08-29 2019-08-28 用于治疗患有类风湿性关节炎的个体的方法和组合物

Country Status (16)

Country Link
US (2) US11319375B2 (cg-RX-API-DMAC7.html)
EP (1) EP3843852A1 (cg-RX-API-DMAC7.html)
JP (1) JP7504871B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260109977A (cg-RX-API-DMAC7.html)
CN (1) CN112955222A (cg-RX-API-DMAC7.html)
AU (2) AU2019329958B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021003206A2 (cg-RX-API-DMAC7.html)
CA (1) CA3110891A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000483A1 (cg-RX-API-DMAC7.html)
IL (1) IL280824A (cg-RX-API-DMAC7.html)
MA (1) MA53481A (cg-RX-API-DMAC7.html)
MX (2) MX2021002422A (cg-RX-API-DMAC7.html)
PH (1) PH12021550416A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202101674QA (cg-RX-API-DMAC7.html)
TW (2) TW202532441A (cg-RX-API-DMAC7.html)
WO (1) WO2020047029A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019001806A2 (pt) 2016-07-29 2019-05-07 Momenta Pharmaceuticals, Inc. anticorpos para fcrn e métodos de uso dos mesmos
JP2022545312A (ja) 2019-04-24 2022-10-27 サノフィ・バイオテクノロジー 関節リウマチの診断及び処置の方法
FR3095698B1 (fr) * 2019-05-03 2021-05-07 Sinnovial Procédé d’estimation de l’efficacité de traitement par un agent anti-CD20 chez un patient atteint de polyarthrite rhumatoïde et en réponse inadéquate a au moins une biothérapie
CA3142710A1 (en) 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
CA3180369A1 (en) * 2020-05-26 2021-12-02 Inka Albrecht Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
KR20230031015A (ko) * 2021-08-26 2023-03-07 주식회사 이뮨메드 자가면역질환의 예방 또는 치료를 위한 항체의약품
CN117138126B (zh) * 2023-08-30 2024-04-09 江苏恰瑞生物科技有限公司 定向清除炎症因子il-6的过滤材料及过滤柱

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006273A1 (en) * 2009-07-15 2011-01-20 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
WO2015034926A1 (en) * 2013-09-03 2015-03-12 Graham L Douglas Treatment methods for rheumatoid arthritis
WO2015116852A1 (en) * 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
CN106413748A (zh) * 2013-11-22 2017-02-15 赛诺菲生物技术公司 用于类风湿性关节炎治疗的组合物及使用该组合物的方法
WO2017155990A1 (en) * 2016-03-07 2017-09-14 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
DE07012626T1 (de) 1991-03-18 2010-01-21 New York University Monoklonale und chimäre Antikörper gegen humanen Tumornekrosefaktor
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
NZ256293A (en) 1992-09-15 1997-06-24 Immunex Corp Method of treating tumour necrosis factor - mediated inflammation by use of tnf antagonist
AU700819B2 (en) 1994-10-07 1999-01-14 Chugai Seiyaku Kabushiki Kaisha Rheumatoid arthritis remedy containing IL-6 antagonist as effective component
ZA971600B (en) 1996-02-26 1997-09-22 Merck & Co Inc Treatment of macular edema.
EP1224189B1 (en) 1999-10-07 2006-01-25 Eli Lilly And Company Condensed dihydroquinolinone derivatives for inhibiting mrp1
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
ME00426B (me) 2003-04-09 2011-10-10 Genentech Inc Liječenje autoimunih bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
AU2005247341B2 (en) 2004-05-06 2008-05-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methods and compositions for the treatment of uveitis
AU2005287406B2 (en) 2004-07-26 2011-08-18 Biogen Ma Inc. Anti-CD154 antibodies
PL1963368T6 (pl) 2005-12-13 2021-02-08 Eli Lilly And Company Przeciwciała anty-IL-17
US20080131374A1 (en) 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
FR2920033B1 (fr) 2007-08-13 2014-08-22 Snecma Turbomachine avec diffuseur
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
RU2565809C2 (ru) 2009-03-19 2015-10-20 Чугаи Сейяку Кабусики Кайся Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
BR112012028557A2 (pt) 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
CA2824089A1 (en) * 2011-02-03 2012-08-09 Santarus, Inc. Selection and treatment of subjects
TWI568888B (zh) 2011-09-15 2017-02-01 第諾拉工業公司 氣體擴散電極及其製法和電化電解池
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
JP7101479B2 (ja) 2014-09-16 2022-07-15 サノフィ・バイオテクノロジー 関節リウマチ患者の健康に関連した生活の質を改善するための組成物
BR112018008900A8 (pt) 2015-11-03 2019-02-26 Regeneron Pharma composições compreendendo anticorpos para il6r para o tratamento de uveíte e edema macular e métodos de uso das mesmas
EP3216461A1 (en) * 2016-03-07 2017-09-13 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011006273A1 (en) * 2009-07-15 2011-01-20 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
WO2015034926A1 (en) * 2013-09-03 2015-03-12 Graham L Douglas Treatment methods for rheumatoid arthritis
CN106413748A (zh) * 2013-11-22 2017-02-15 赛诺菲生物技术公司 用于类风湿性关节炎治疗的组合物及使用该组合物的方法
WO2015116852A1 (en) * 2014-01-29 2015-08-06 Regeneron Pharmaceuticals, Inc. Methods for treating rheumatoid arthritis by administering an il-6r antibody
WO2017155990A1 (en) * 2016-03-07 2017-09-14 Sanofi Biotechnology Compositions and methods for treating rheumatoid arthritis

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANITA BOYAPATI ET AL.: "High baseline serum IL-6 identifies a subgroup of rheumatoid arthritis patients with rapid joint damage and clinical progression and predicts increased sarilumab treatment response", 《RHEUMATOLOGY》, vol. 58, pages 055642507 *
MARIA GABRIELLA RAIMONDO ET AL.: "Profile of sarilumab and its potential in the treatment of rheumatoid arthritis", 《DRUG DESIGN, DEVELOPMENT AND THERAPY》, pages 1593 - 1603 *
SOO-JIN CHUNG ET AL.: "The correlation between increased serum concentration of Interleukin-6 family cytokines and disease activity in rheumatoid arthritis patients", 《YMJ.》, vol. 52, no. 1, pages 113 - 120, XP055212552, DOI: 10.3349/ymj.2011.52.1.113 *
TOM W J HUIZINGA ET AL.: "Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate:efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial", 《ANN RHEUM DIS.》, vol. 73, pages 1626 - 1634, XP055348613, DOI: 10.1136/annrheumdis-2013-204405 *

Also Published As

Publication number Publication date
CA3110891A1 (en) 2020-03-05
US20200102395A1 (en) 2020-04-02
AU2019329958A1 (en) 2021-03-18
JP7504871B2 (ja) 2024-06-24
IL280824A (en) 2021-04-29
SG11202101674QA (en) 2021-03-30
EP3843852A1 (en) 2021-07-07
WO2020047029A1 (en) 2020-03-05
TW202026035A (zh) 2020-07-16
TWI868074B (zh) 2025-01-01
US20230059376A1 (en) 2023-02-23
AU2019329958B2 (en) 2025-05-29
KR20260109977A (ko) 2026-07-13
MA53481A (fr) 2021-07-07
BR112021003206A2 (pt) 2021-05-25
KR20210049871A (ko) 2021-05-06
PH12021550416A1 (en) 2021-09-27
AU2025203365A1 (en) 2025-05-29
TW202532441A (zh) 2025-08-16
MX2021002422A (es) 2021-07-15
US11319375B2 (en) 2022-05-03
CL2021000483A1 (es) 2021-07-19
JP2022502350A (ja) 2022-01-11
MX2025010592A (es) 2025-10-01

Similar Documents

Publication Publication Date Title
JP7504871B2 (ja) 関節リウマチを有する対象を治療するための方法および組成物
EP3111954B1 (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies
US20260108601A1 (en) Method of diagnosis and treatment of rheumatoid arthritis
JP2022534794A (ja) 関節リウマチを有する対象における疼痛を治療するための組成物および方法
RU2828027C2 (ru) Способы диагностики и лечения ревматоидного артрита
EA045703B1 (ru) Способы и композиции для лечения субъектов, страдающих ревматоидным артритом
EA053078B1 (ru) Способы и композиции для лечения субъектов, страдающих ревматоидным артритом
HK40083901A (en) Methods of treating rheumatoid arthritis using il-17 antagonists
HK40010039A (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK40035240A (en) Methods of treating psoriatic arthritis using il-17 antagonists
HK1229257B (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies
HK1229257A1 (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination